Friday, July 31, 2015

Merck profit jumps 67 percent, but overall sales lower than expected

Merck reported a 67 percent profit increase Friday for the first quarter of this year compared to the same period in 2011, despite lower sales than some analysts predicted.

Merck profit jumps 67 percent, but overall sales lower than expected

0 comments

Merck reported a 67 percent profit increase Friday for the first quarter of this year compared to the same period in 2011, despite lower sales than some analysts predicted.

The global drug maker, which is based in Whitehouse Station, N.J. and has big operations in the Philadelphia suburbs, got the profit bump by spending less.

"We're trying to manage our cost structure going forward," Merck chief executive officer Ken Frazier said in a conference call with Wall Street analysts.

The sales highlight for Merck was in the diabetes area. The asthma drug Singular remains Merck's top seller, with $1.34 billion in sales in the first quarter, a three percent increase. But the second-best seller is the diabetes pill Januvia, which had $919 million in sales, an increase of 24 percent over the same period in 2011.

More coverage
 
Corporate earnings in region doing well

Merck said its net income was $1.74 billion, which equates to 56 cents per share. That compared to $1.04 billion and 34 cents per share in the first quarter of 2011.

The total sales for the first quarter were $11.74 billion, just 1 percent above the the $11.58 billion a year earlier.

Merck stock was at $38.87 in the first few minutes of trading on Friday.

The financial charts with the Merck earnings release is here.

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Also on Philly.com:
letter icon Newsletter